Skip to main content

VivoSim Labs, INC.

VIVS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001497253

In the last 90 days, VivoSim Labs, INC. insiders filed 1 open-market purchase and 0 sales; 25 institutions reported holding it in 13F filings for Q2 2026, worth $109.7K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by VivoSim Labs, INC. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $2.80K in total
Open-market sells
0 filings
Insiders trading
1
Net value
+$2.80K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for VivoSim Labs, INC., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for VivoSim Labs, INC.
NameTitleLast reported holdingLast filingFilings, past year
Lialin Tony SergeChief Commercial Officer10,000Sep 1, 20261
Stern Adam KDirector19,899Jan 29, 20261
Murphy KeithEXECUTIVE CHAIRMAN26,053Jan 29, 20261
Cohen Douglas JayDirector20,732Jan 29, 20261
Milhous Alison TjosvoldDirector19,899Jan 29, 20261
Gobel DavidDirector15,000Jan 29, 20262
Sethi Amar AkhtarChief Scientific Officer–Nov 26, 20251
Joshi VaidehiDirector58,821Aug 9, 20240
Jurgensen Thomas EGeneral Counsel & Secretary–Oct 20, 20220
Miner Jeffrey N.Chief Scientific Officer–Oct 20, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 1, 2026 (view filing)4:01 PM ETAug 311 dayLialin Tony SergeChief Commercial OfficerPPurchase+10.0K$0.2804+$2.80KNew position10.0K after
Nov 19, 2025 (view filing)Nov 172 daysGobel DavidDirectorSSale+3.27K$2.24+$7.32KNew position0 after
Nov 17, 2023 (view filing)Nov 152 daysGobel DavidDirectorSSale−19.6K$1.62−$31.8K−100.0%0 after
Aug 19, 2021 (view filing)Aug 172 daysCohen Douglas JayDirectorPPurchase+8.75K$6.72+$58.8K+700.0%10.0K after
Aug 19, 2021 (view filing)Aug 172 daysCohen Douglas JayDirectorPPurchase+2.00K$6.73+$13.5KNew position1.00K after2 lots